


Ophthalmic Drugs Market to Expand from USD 35.4 Billion in 2024 to USD 67.9 Billion by 2035 – TMR Outlook

Global Ophthalmic Drugs Industry Sees Steady Expansion in Next Decade

WILMINGTON, DE, UNITED STATES, August 13, 2025 /EINPresswire.com/ -- [Ophthalmic Drugs Market](#) Outlook 2035

The global ophthalmic drugs market was valued at US\$ 35.4 Billion in 2024 and is projected to surpass US\$ 67.9 Billion by 2035, expanding at a CAGR of 6.1% from 2025 to 2035. Rising prevalence of eye disorders such as glaucoma, cataracts, and age-related macular degeneration is driving market growth. Increasing adoption of advanced drug delivery systems and ongoing R&D investments in novel ophthalmic therapeutics are further boosting industry expansion.



Ophthalmic Drugs Market Outlook 2035



Rising Eye Care Demand to Drive Global Ophthalmic Drugs Market from USD 35.4 Billion in 2024 to USD 67.9 Billion by 2035"

Latest Report by Transparency Market Research, Inc.

Don't miss out on the latest market intelligence. Get your sample report copy today @

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1769

Ophthalmic drugs encompass prescription and OTC therapies formulated for ocular use, including anti-VEGF biologics, anti-infectives, anti-inflammatories, anti-glaucoma agents, lubricants, and allergy medications. Delivery formats range from eye drops and ointments to

implants, inserts, and intravitreal injections designed to maximize corneal penetration and patient adherence.

With more screening for diabetic eye disease, innovation in drug delivery (e.g., depot implants, punctal plugs, and nano-formulations), and the emergence of biosimilars, the ophthalmic drugs market is seeing accelerated adoption across both specialty and primary care settings.

Analyst Viewpoints

The Ophthalmic Drugs Market is shifting from short-acting, adherence-challenged topicals to longer-acting, targeted therapies. Anti-VEGF agents continue to dominate retinal care, while sustained-release steroids, ROCK inhibitors, and novel tear-film stabilizers broaden options across glaucoma and dry eye.

Analysts see three themes shaping the next decade:

1. Durability & convenience: Fewer clinic visits via extended-interval dosing and implants.
2. Precision therapy: [Biomarkers](#) and imaging-driven regimens to personalize care.
3. Affordability & access: Biosimilars and combination therapies to expand reach in cost-sensitive markets.

As payers emphasize real-world outcomes, companies that pair efficacy with adherence—and back it with strong health-economic data—will lead.

Analysis of Key Players in the Ophthalmic Drugs Market

The global ophthalmic drugs market is highly competitive and research-driven, with major players investing heavily in R&D for advanced therapeutics such as anti-VEGF therapy, gene therapy, and innovative drug delivery systems. The focus is on improving drug efficacy, patient compliance, and treatment accessibility.

Pharmaceutical leaders are conducting large-scale clinical trials to assess the safety and effectiveness of next-generation drugs targeting a wide range of ocular conditions.

Key companies operating in the market include:

Alcon Inc., Novartis AG, Bausch + Lomb, Merck & Co., Inc., Regeneron Pharmaceuticals Inc., Coherus BioSciences, Inc., Pfizer Inc., AbbVie, RIBOMIC, Santen Pharmaceutical Co., Ltd., Cipla Limited, Lupin Pharmaceuticals, Inc., Ocular Therapeutix, Inc., Novaliq GmbH, ZEXUS PHARMA, and Grevis Pharmaceuticals Pvt. Ltd.

Each of these players has been profiled in the ophthalmic drugs market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments in the Ophthalmic Drugs Market

- May 2025 – F. Hoffmann-La Roche AG

Received U.S. FDA approval for Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR). Susvimo is a surgically implanted eye device that delivers a personalized, continuous dose of ranibizumab, reducing the need for frequent injections. Approval was granted based on positive one-year Phase III Pavilion study results.

- August 2024 – Sandoz Inc.

Secured U.S. FDA approval for Enzeevu (aflibercept-abzv) 2 mg vial kit and pre-filled syringe for intravitreal injection in patients with neovascular age-related macular degeneration (nAMD). The FDA also granted interchangeability status with the reference medicine Eylea (Regeneron/Bayer), providing patients with a cost-effective alternative while maintaining therapeutic equivalence.

Key Growth Drivers

1. Aging Population & Disease Burden

Higher incidence of cataract, glaucoma, AMD, and DME drives sustained demand.

2. Innovation in Drug Delivery

Implants, inserts, and long-acting formulations enhance durability and adherence.

3. Retinal Therapeutics Momentum

Anti-VEGF and emerging modalities continue to anchor high-value segments.

4. Biosimilars & Market Access

Lower-cost options increase treatment initiation and persistence.

5. Digital & Diagnostics Integration

OCT, fundus imaging, and AI triage tools support earlier, more frequent treatment.

Discuss implications for your business. Request Sample Research PDF @

<https://www.transparencymarketresearch.com/ophthalmic-drugs-market.html>

Opportunities

- Durable, Long-Acting Retinal Therapies

Extended-interval anti-VEGF, TKI platforms, refillable reservoirs.

- Novel Mechanisms in Dry Eye & Ocular Surface

Tear-film stabilizers, anti-inflammatory pathways, neurostimulation.

- Glaucoma Combination & Device-Drug Hybrids

Fixed-dose combos and sustained-release adjuncts to reduce IOP variability.

- Biosimilars & Emerging Markets

Portfolio localization and pricing strategies to unlock volume growth.

- Precision Ophthalmology & Real-World Evidence

Imaging biomarkers and outcomes contracts to support value-based care.

Challenges

- Adherence & Treatment Burden

Frequent dosing/injections can limit persistence and outcomes.

- Pricing & Reimbursement Pressure

Budget constraints and step-therapy rules affect uptake of premium drugs.

- Sterility & Stability Constraints

Ocular formulations face strict preservative and shelf-life requirements.

- Competition from Devices & Procedures

MIGS and laser therapies may offset demand for certain drug classes.

- Regulatory & Safety Hurdles

Long-term intraocular safety and preservative toxicity require vigilance.

Market Segmentation

By Drug Class:

Anti-VEGF Agents • Anti-inflammatories (steroids/NSAIDs) • Anti-glaucoma (prostaglandin analogs, beta-blockers, alpha agonists, CAIs, Rho-kinase inhibitors, combos) • Anti-infectives • Lubricants & Dry-Eye Therapies • Antihistamines & Mast-Cell Stabilizers • Others (neuroprotectives, TKIs)

By Indication:

Age-Related Macular Degeneration (AMD) • Diabetic Retinopathy/Diabetic Macular Edema (DR/DME) • Retinal Vein Occlusion (RVO) • Glaucoma/Ocular Hypertension • Dry Eye Disease • Allergic Conjunctivitis • Post-operative Inflammation & Pain • Ocular Infections

By Route of Administration:

Topical (drops/ointments/gels) • Intravitreal • Implant/Insert • Systemic

By Distribution Channel:

Hospital Pharmacies • Retail Pharmacies • Specialty Clinics • Online Pharmacies

By Region:

North America • Europe • Asia-Pacific • Middle East & Africa • Latin America

Future Prospectus

By 2035, the ophthalmic drugs landscape will be defined by durability, personalization, and access. Expect broader adoption of extended-interval retinal therapies, sustained-release glaucoma solutions, and preservative-free formulations that improve tolerability. Biosimilars will expand affordability, while AI-driven screening and remote monitoring increase treatment initiation and persistence. Asia-Pacific is poised for above-average growth on the back of demographic trends and care infrastructure investments, while North America and Europe lead innovation and early adoption.

To buy this comprehensive market research report, click here to inquire @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1769<ype=S

What Is in This Report?

- Global & regional market size forecasts (2023–2035)
- Growth drivers, challenges, and opportunity mapping
- Detailed segmentation by drug class, indication, route, and channel
- Technology & delivery innovations (implants, inserts, long-acting)
- Competitive landscape with profiles & recent strategic moves
- Pricing, access, and reimbursement analysis
- Regulatory outlook & safety considerations
- Porter's Five Forces, SWOT, and actionable strategy playbook

Why Buy This Report?

1. Informed Decisions

Data-backed forecasts and therapy-area insights to guide strategy.

2. Innovation Radar

Spot winning mechanisms, delivery tech, and lifecycle pathways.

3. Competitive Benchmarking

Understand positioning, pipelines, partnerships, and launch cadence.

4. Market Entry & Expansion

Identify high-growth regions, channels, and indication whitespaces.

5. Access & Affordability Strategy

Navigate biosimilars, HTA requirements, and outcomes contracts.

6. Future-Proofing

Align roadmaps with durability, precision care, and digital screening trends.

Conclusion

The Ophthalmic Drugs Market is moving beyond conventional, short-acting drops to a durable, patient-centric future. Companies that deliver longer-lasting efficacy, simplify treatment pathways, and demonstrate real-world value—while ensuring access through smart pricing and biosimilar strategies—will set the pace. This report is your blueprint for capturing growth across retinal, glaucoma, and ocular surface segments in the decade ahead.

More Trending Related Research Reports-

Ophthalmic Ultrasound Systems Market -

<https://www.transparencymarketresearch.com/ophthalmic-ultrasound-systems-market.html>

Ophthalmic Optics and Instrument Market -

<https://www.transparencymarketresearch.com/ophthalmic-optics-instrument-market.html>

Ophthalmic Lasers Market - <https://www.transparencymarketresearch.com/ophthalmic-lasers-market.html>

Ophthalmic Surgical Technologies Market -

<https://www.transparencymarketresearch.com/ophthalmic-surgical-technologies-market.html>

Ophthalmic Surgical Devices and Therapeutics (Eye Care) Market -

<https://www.transparencymarketresearch.com/ophthalmic-surgical-devices-therapeutics-market.html>

Ophthalmic Perimeters Market - <https://www.transparencymarketresearch.com/ophthalmic-perimeters-market.html>

Ophthalmic Knives Market - <https://www.transparencymarketresearch.com/ophthalmic-knives-market.html>

Ophthalmic Sutures Market - <https://www.transparencymarketresearch.com/ophthalmic-sutures-market.html>

Ophthalmic Packaging Market - <https://www.transparencymarketresearch.com/north-america-ophthalmic-packaging-market.html>

Lifitegrast Ophthalmic Solution Market -

<https://www.transparencymarketresearch.com/lifitegrast-ophthalmic-solution-market.html>

Osteoporosis Drugs Market - <https://www.transparencymarketresearch.com/osteoporosis-drug-market.html>

Epigenetics Drugs and Diagnostic Technologies Market -

<https://www.transparencymarketresearch.com/epigenetics-market.html>

Kidney Cancer Drugs Market - <https://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html>

CINV Existing and Pipeline Drugs Market - <https://www.transparencymarketresearch.com/cinv-market.html>

Multiple Sclerosis Drugs Market - <https://www.transparencymarketresearch.com/multiple-sclerosis-drugs.html>

Depression Drugs Market - <https://www.transparencymarketresearch.com/depression-drug-market.html>

Alzheimer's Drugs Market - <https://www.transparencymarketresearch.com/alzheimers-drugs-market.html>

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: <https://www.transparencymarketresearch.com>
Blog: <https://tmrblog.com>
Email: sales@transparencymarketresearch.com

Atil Chaudhari

Transparency Market Research Inc.
+ +1 518-618-1030

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[YouTube](#)

[X](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/839511483>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.